Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical composition used for delaying development process of early parkinson's disease

A composition and drug technology, applied in the field of medicine, can solve problems such as high manufacturing cost, high drug concentration, and limitation of clinical promotion and application

Inactive Publication Date: 2020-10-13
深圳市旷逸生物科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its high manufacturing cost and ultra-high drug concentration limit the clinical promotion and application of NMN in the treatment of PD. Therefore, reducing the manufacturing cost or lowering the drug concentration has become the key to using NMN for PD treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical composition used for delaying development process of early parkinson's disease
  • Medical composition used for delaying development process of early parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The preparation of embodiment 1 alpine edelweiss extract

[0032] Accurately weigh 1000g of alpine edelweiss plant cell culture (moisture content above 90%), after fully suspending, add 2000mL of 95% ethanol at a material-to-liquid ratio of 1:2 (m / v), stir and mix, and ultrasonically treat 15min (ultrasonic power: 300w, ultrasonic temperature: 25°C); add 8L of pure water to the ultrasonically broken wall treatment product, and extract at a high temperature of 80-120°C for 1.5h; centrifuge the extracted product at 10,000g for 10min to take the supernatant, The supernatant was concentrated under reduced pressure and then freeze-dried to obtain the edelweiss alpine extract.

Embodiment 2

[0033] The preparation of embodiment 2 pharmaceutical compositions

[0034] After accurately weighing 4g of NMN and 80g of alpine edelweiss extract and mixing them uniformly in equal proportions, the pharmaceutical composition is obtained.

Embodiment 3

[0035] Embodiment 3 MPTP model mouse behavior test

[0036] Experimental Materials:

[0037] 1) Experimental animals:

[0038] 8-week-old C57BL / 6 male mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., free to eat and drink, and kept in an animal room with alternating light and dark for 12 hours at an average temperature of 25°C.

[0039] 2) Main instruments:

[0040] Self-made mice climbing rods and hanging chambers.

[0041] 3) Main reagents:

[0042] MPTP: Sigma

[0043] 4) Drugs:

[0044] NMN: Bangtai Bioengineering (Shenzhen) Co., Ltd.;

[0045] Pharmaceutical composition: self-made according to Example 2.

[0046] experimental method:

[0047] 1) Establishment of mouse PD model:

[0048] Screening of mice by pole-climbing method: Modeling starts after one week of temporary breeding. Before modeling, mice are trained to climb poles. First, mice are guided to climb from the top of the pole to the bottom of the pole within 15 s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a medical composition containing NMN, and a preparation method of the medical composition, and the medical composition is used for delaying the development process of early parkinson's disease. The NMN has a certain effect on delaying the development process of the early parkinson's disease of a PD model mouse, and shows dosage dependence, the delaying effect of the NMN is lower than that of the medical composition, and in the same medication duration, the effect of the composition on delaying the development of the early parkinson's disease of the PD model mouse is notably better than that of the NMN. The composition shows time dependence for delaying the development process of the early parkinson's disease of the PD model mouse, the longer the medication time is, the better the delaying effect is, but the treatment effect is not as good as the prevention effect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically, the invention provides a pharmaceutical composition for delaying the development process of early Parkinson's disease. Background technique [0002] Parkinson's disease (Parkinson's disease, PD) is a common chronic progressive neurodegenerative lifelong disease in the elderly. The content of dopamine transmitter was significantly reduced. Oxidative stress damage is considered to be one of the important causes of Parkinson's pathogenesis. The pathogenic mechanism is: there is a free radical scavenging system in normal organisms, and in the brain there are mainly superoxide dismutase, glutathione peroxide Enzymes and reduced glutathione, etc., can remove excess free radicals in time to prevent brain cells from being damaged by them. Under normal circumstances, the production and scavenging of free radicals are in a balanced state. Once the balance is broken, the production of f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/28A61K31/706A61P25/16
CPCA61K31/706A61K36/28A61K2236/30A61P25/16A61K2300/00
Inventor 沈洁沈艳
Owner 深圳市旷逸生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com